Although it is recommended that women of childbearing age consult their healthcare team regarding disease control and family planning early on in their reproductive journey, fewer than half (46%) of women surveyed visited a healthcare professional (HCP) prior to becoming pregnant, and a majority of these women (69%) had to initiate these discussions themselves. While information provided by HCPs was generally satisfactory, some patients still felt they lacked information on the impact of their treatment decisions on pregnancy (38%) and breastfeeding (24%). Many women surveyed chose to either delay their plans to become pregnant (54%), or to discontinue their treatment before becoming pregnant (20%), and in the majority of cases, women indicated it was their idea to do so (68%). Almost half (46%) of women who delayed their decision to become a mother said they did so out of concern they may pass their condition on to their child.
“Survey results suggest that for some, the decision to delay pregnancy or stop treatment may be linked to a lack of guidance and reliable information, indicating a strong need for greater disease awareness and access to trustworthy educational materials to inform discussions about treatment and family planning,” said Dr. Rebecca Fischer-Betz, Department of Rheumatology, University Hospital of Düsseldorf, Duesseldorf, Germany. “Findings support the idea that it’s important for patients and HCPs to work collaboratively from the start to ensure women have the information they need to make informed decisions regarding treatment and family planning, assuring optimal outcomes for both mother and child.”
About a third (32%) of women reported having inadequately controlled disease activity during pregnancy, while 22% reported disease worsening. Determining a treatment plan that is suitable during family planning is a complex decision to be made in consultation with one’s healthcare team, yet only 65% percent of patients reported having aligned a treatment plan between their different HCPs.
“Navigating chronic rheumatic diseases and pregnancy can lead to uncertainty for many women,” said Emmanuel Caeymaex, Executive Vice President, UCB Immunology. “These findings have informed global initiatives, such as the Autoimmune Motherhood (AIM) Movement and other efforts across the U.S. and Europe, to inform and connect women, helping support the best outcomes possible. Our goal is to empower women of childbearing age to have fruitful conversations with their healthcare team about managing their condition during their reproductive health journey. This kind of specialized support for patients with specific unmet needs is core to UCB’s patient value commitment.”
To support women living with chronic rheumatic diseases as they navigate their childbearing years, UCB is launching the AIM Movement, a global campaign with local reach designed to spread awareness about managing chronic rheumatic diseases throughout all stages of reproductive journey and encourage women to have informed conversations with their healthcare professionals. The AIM campaign awareness efforts will be rolled out in Europe and North America, in partnership with various local advocacy patient groups.
About the Survey
A total of 1,052 women living with chronic inflammatory diseases were surveyed across Europe (Germany, France, UK, Italy and Spain), the United States and Japan. Results presented this week at EULAR 2018 specifically highlight the experience of women aged 18-45 living with chronic rheumatic diseases (622/1052 participants), including axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and rheumatoid arthritis (RA).
For further information, UCB:
Global Communications, UCB
Investor Relations, UCB
Andrea Levin Christopher,
Immunology Communications, UCB
T +32.2.559.9178, firstname.lastname@example.org
T +32.2.559.94.14, email@example.com
T +32.2.559.92.64, firstname.lastname@example.org
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology or neurology. With more than 7,500 people in approximately 40 countries, the company generated revenue of € 4.5 billion in 2017. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
Forward looking statements – UCB
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.
View original content:http://www.prnewswire.com/news-releases/new-study-presented-at-the-annual-european-congress-of-rheumatology-eular-2018-reveals-insights-about-women-with-chronic-rheumatic-diseases-during-their-pregnancy-journey-300666685.html
Read on The Source